Japanese Pharma Stock News

TSE:6988
TSE:6988Chemicals

How Investors May Respond To Nitto Denko (TSE:6988) Upgrading Guidance On IT And Smartphone Materials Demand

Nitto Denko Corporation recently raised its full-year guidance for the year ending March 31, 2026, now projecting revenue of ¥1,027,000 million, operating profit of ¥186,000 million and profit attributable to owners of the parent of ¥136,000 million, alongside higher expected basic earnings per share of ¥200.56. The company linked this upgraded outlook to stronger-than-expected demand for materials used in IT devices and high-end smartphones, while nine-month sales to December 2025 grew...
TSE:7011
TSE:7011Machinery

Mitsubishi Heavy (TSE:7011) Is Up 10.3% After Raising Guidance And Revamping Segment Leadership - Has The Bull Case Changed?

In February 2026, Mitsubishi Heavy Industries reported nine‑month sales of ¥3,326,976 million and net income of ¥210,996 million, and raised its full‑year fiscal 2025–26 earnings guidance, while also announcing multiple executive and board changes effective from March 31 and April 1, 2026. The reshuffle places new executive vice presidents in charge of Energy Systems, Nuclear Energy Systems, and Commercial Aviation Systems, signaling internal emphasis on these core business segments...
TSE:4203
TSE:4203Chemicals

Sumitomo Bakelite (TSE:4203) Valuation Check After Upgraded Guidance On Strong Semiconductor And AI Demand

Why Sumitomo Bakelite (TSE:4203) is in focus after earnings and guidance Sumitomo Bakelite (TSE:4203) is back on investors’ radar after reporting nine month earnings to December 31, 2025, and lifting its full year fiscal 2026 guidance on stronger semiconductor materials demand. See our latest analysis for Sumitomo Bakelite. The earnings beat and upgraded guidance appear to be feeding into steady momentum, with the 1 month share price return of 8.58% and year to date share price return of...